Advantage Trust Company’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Advantage Trust Company’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$672K	Buy	4,245 +600	+16%	+$81.1K	0.24%	29
2026 Q1	$466K	Hold	3,645	–	–	0.21%	29
2025 Q4	$444K	Sell	3,645 -600	-14%	-$68.8K	0.2%	28
2025 Q3	$425K	Hold	4,245	–	–	0.19%	38
2025 Q2	$352K	Buy	4,245 +500	+13%	+$39.9K	0.17%	46
2025 Q1	$304K	Sell	3,745 -900	-19%	-$80.4K	0.18%	35
2024 Q4	$418K	Sell	4,645 -1,200	-21%	-$116K	0.25%	30
2024 Q3	$577K	Sell	5,845 -600	-9%	-$59K	0.39%	23
2024 Q2	$598K	Hold	6,445	–	–	0.43%	22
2024 Q1	$612K	Hold	6,445	–	–	0.45%	22
2023 Q4	$575K	Buy	+6,445	New	+$479K	0.45%	21

Other funds holding XBI

PSP Research Newtown Square, Pennsylvania $188M AUM

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

RFM

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

NHFG

New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return

MFS

Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

LRPA

L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

LHWM

Lake Hills Wealth Management Austin, Texas $220M AUM 39.11% 1-Year Est. Return

Advantage Trust Company's XBI Position: Q2 2026 in Review

Advantage Trust Company increased its State Street SPDR S&P Biotech ETF (XBI) stake by 16% in Q2 2026, buying an estimated $81.1K and bringing the position to 4,245 shares worth $672K. The position accounts for 0.24% of the portfolio, ranked #29.

Advantage Trust Company first reported a position in XBI in Q4 2023 and has held it in 11 quarters since. 261 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Advantage Trust Company held 4,245 shares of State Street SPDR S&P Biotech ETF worth $672K as of Q2 2026.
Advantage Trust Company bought 600 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $81.1K.
State Street SPDR S&P Biotech ETF made up 0.24% of Advantage Trust Company's portfolio in Q2 2026, its #29 holding.
Advantage Trust Company first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and has held it in 11 quarters since.
261 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Advantage Trust Company's 13F filing for Q2 2026, filed 17 Jul 2026.